MBII Key Statistics, Chart & Performance
The current stock price of MBII is 0.7981 null. In the past month the price decreased by -28.1%. In the past year, price decreased by -43.8%.
MBII Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CTVA | CORTEVA INC | 20.03 | 46.28B | ||
| CF | CF INDUSTRIES HOLDINGS INC | 9.69 | 12.60B | ||
| MOS | MOSAIC CO/THE | 10.33 | 8.16B | ||
| SMG | SCOTTS MIRACLE-GRO CO | 16.5 | 3.56B | ||
| FMC | FMC CORP | 4.27 | 1.89B | ||
| UAN | CVR PARTNERS LP | 9.4 | 1.20B | ||
| IPI | INTREPID POTASH INC | 37.37 | 421.57M | ||
| AVD | AMERICAN VANGUARD CORP | N/A | 111.03M | ||
| NITO | N2OFF INC | N/A | 4.63M |
Related stock screener links
About MBII
Company Profile
Marrone Bio Innovations, Inc. engages in the provision of biological-based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. The company is headquartered in Raleigh, North Carolina and currently employs 153 full-time employees. The company went IPO on 2013-08-02. The firm offers 18 products that include Emergen, Foramin, Foramin ST, Grandevo, Haven, Jet-Ag, Jet-Oxide, Majestene, Pacesetter, Regalia, Stargus, UBP, UBP ST, Venerate, Zelto, and others. Its pipeline consists of products in three categories: bioprotection, seed and soil health, and plant health. Its product categories include products, which are referred to as biopesticides, bioinsecticides, bionematicides, biofungicides, biostimulants and bionutrition. The firm's end markets are row crops, such as corn and soybeans; fruits and vegetables, such as tomatoes, leafy greens and cucurbits; trees, nuts and vines, such as almonds and grapes; and greenhouse production, such as ornamentals and medicinal plants.
Company Info
Marrone Bio Innovations Inc
7780-420 Brier Creek Parkway, Raleigh
Raleigh NORTH CAROLINA 95618 US
CEO: Kevin Helash
Employees: 153
Phone: 15307502800.0
Marrone Bio Innovations Inc / MBII FAQ
What does MBII do?
Marrone Bio Innovations, Inc. engages in the provision of biological-based solutions for agricultural crops, turf protection, seed treatment, plant health and waterway systems. The company is headquartered in Raleigh, North Carolina and currently employs 153 full-time employees. The company went IPO on 2013-08-02. The firm offers 18 products that include Emergen, Foramin, Foramin ST, Grandevo, Haven, Jet-Ag, Jet-Oxide, Majestene, Pacesetter, Regalia, Stargus, UBP, UBP ST, Venerate, Zelto, and others. Its pipeline consists of products in three categories: bioprotection, seed and soil health, and plant health. Its product categories include products, which are referred to as biopesticides, bioinsecticides, bionematicides, biofungicides, biostimulants and bionutrition. The firm's end markets are row crops, such as corn and soybeans; fruits and vegetables, such as tomatoes, leafy greens and cucurbits; trees, nuts and vines, such as almonds and grapes; and greenhouse production, such as ornamentals and medicinal plants.
What is the stock price of Marrone Bio Innovations Inc today?
The current stock price of MBII is 0.7981 null. The price decreased by -20.19% in the last trading session.
Does Marrone Bio Innovations Inc pay dividends?
MBII does not pay a dividend.
What is the ChartMill technical and fundamental rating of MBII stock?
MBII has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists MBII stock?
MBII stock is listed on the Nasdaq exchange.
What sector and industry does Marrone Bio Innovations Inc belong to?
Marrone Bio Innovations Inc (MBII) operates in the Materials sector and the Chemicals industry.
What is the Price/Earnings (PE) ratio of Marrone Bio Innovations Inc (MBII)?
Marrone Bio Innovations Inc (MBII) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
MBII Technical Analysis
MBII Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MBII. MBII has a bad profitability rating. Also its financial health evaluation is rather negative.
MBII Financial Highlights
Over the last trailing twelve months MBII reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by 0% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -47.09% | ||
| ROA | -27.42% | ||
| ROE | N/A | ||
| Debt/Equity | 0.33 |
MBII Forecast & Estimates
10 analysts have analysed MBII and the average price target is 1.4 null. This implies a price increase of 75.73% is expected in the next year compared to the current price of 0.7981.
For the next year, analysts expect an EPS growth of -7.1% and a revenue growth 29.1% for MBII